Class II

Drug Recall: Levothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90-count bottles (NDC 0378-1815-77) and b) 1000-count bottles (NDC 0378-1815-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgan

Viatris Inc · November 18, 2024

Reason for Recall

Superpotent Drug and Subpotent Drug: potency failures obtained

Product Description

Levothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90-count bottles (NDC 0378-1815-77) and b) 1000-count bottles (NDC 0378-1815-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Distribution

Nationwide within the United States and Puerto Rico

States Affected

NATIONWIDE

Quantity Affected

9,828 bottles

Source: FDA (openFDA Drug Enforcement)

Recall number: D-0120-2025

Status: ongoing

SafeCheck provides drug interaction information from FDA-approved product labeling (openFDA). This is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions.